Welcome, Guest. Please login or register.
November 24, 2024, 05:53:32 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 222
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 31
Total: 31

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Mavyret Cures High Rate of Those with Genotype 3 of Hepatitis C  (Read 6130 times)

0 Members and 2 Guests are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Mavyret Cures High Rate of Those with Genotype 3 of Hepatitis C
« on: November 27, 2017, 11:36:33 am »
AbbVie’s hepatitis C virus (HCV) regimen Mavyret (glecaprevir/pibrentasvir) is highly effective among those with genotype 3 of the virus, considered the most difficult genotype to treat.

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC, researchers conducted an analysis of safety and efficacy data from five Phase II and III studies of Mavyret among 571 individuals with genotype 3 of hep C who were first-timers to treatment.

For more...
https://www.hepmag.com/article/maviret-cures-high-rate-genotype-3-hepatitis-c

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.